| Autor: |
Shu-Chen Lu, Michelle Chen, Larissa Atangan, Elizabeth A. Killion, Renee Komorowski, Yuan Cheng, Chawita Netirojjanakul, James R. Falsey, Marina Stolina, Denise Dwyer, Clarence Hale, Shanaka Stanislaus, Todd Hager, Veena A. Thomas, John M. Harrold, David J. Lloyd, Murielle M. Véniant |
| Jazyk: |
angličtina |
| Rok vydání: |
2021 |
| Předmět: |
|
| Zdroj: |
Cell Reports Medicine, Vol 2, Iss 5, Pp 100263- (2021) |
| Druh dokumentu: |
article |
| ISSN: |
2666-3791 |
| DOI: |
10.1016/j.xcrm.2021.100263 |
| Popis: |
Summary: Glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) regulate glucose and energy homeostasis. Targeting both pathways with GIP receptor (GIPR) antagonist antibody (GIPR-Ab) and GLP-1 receptor (GLP-1R) agonist, by generating GIPR-Ab/GLP-1 bispecific molecules, is an approach for treating obesity and its comorbidities. In mice and monkeys, these molecules reduce body weight (BW) and improve many metabolic parameters. BW loss is greater with GIPR-Ab/GLP-1 than with GIPR-Ab or a control antibody conjugate, suggesting synergistic effects. GIPR-Ab/GLP-1 also reduces the respiratory exchange ratio in DIO mice. Simultaneous receptor binding and rapid receptor internalization by GIPR-Ab/GLP-1 amplify endosomal cAMP production in recombinant cells expressing both receptors. This may explain the efficacy of the bispecific molecules. Overall, our GIPR-Ab/GLP-1 molecules promote BW loss, and they may be used for treating obesity. |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
